FDA Approves Imfinzi Combo for dMMR Advanced Endometrial Cancer

Jun 17, 2024, 08:12 AM

The U.S. Food and Drug Administration (FDA) has approved the use of durvalumab in combination with carboplatin and paclitaxel, followed by single-agent durvalumab, for adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR). This approval, announced on June 14, is based on the Duo-E subgroup analysis. Durvalumab, marketed as IMFINZI®, is produced by AstraZeneca (AZN).